Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Bryan Haugen to Animals

This is a "connection" page, showing publications Bryan Haugen has written about Animals.

 
Connection Strength
  
 
 
0.367
  
  1. Jeon MJ, Haugen BR. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models. Endocrinol Metab (Seoul). 2022 12; 37(6):830-838.
    View in: PubMed
    Score: 0.043
  2. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048.
    View in: PubMed
    Score: 0.033
  3. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1436-44.
    View in: PubMed
    Score: 0.024
  4. Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014 Mar 19; 13:62.
    View in: PubMed
    Score: 0.024
  5. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun; 34(3):439-55.
    View in: PubMed
    Score: 0.022
  6. Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid. 2011 Sep; 21(9):941-4.
    View in: PubMed
    Score: 0.020
  7. Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM, Haugen BR. A rexinoid antagonist increases the hypothalamic-pituitary-thyroid set point in mice and thyrotrope cells. Mol Cell Endocrinol. 2011 Jun 06; 339(1-2):1-6.
    View in: PubMed
    Score: 0.019
  8. Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer. 2009 Mar 06; 8:16.
    View in: PubMed
    Score: 0.017
  9. Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res. 2008 Jan 15; 14(2):589-96.
    View in: PubMed
    Score: 0.015
  10. Sharma V, Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology. 2006 Mar; 147(3):1438-51.
    View in: PubMed
    Score: 0.013
  11. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep; 4(3):175-80.
    View in: PubMed
    Score: 0.012
  12. Haugen BR, Jensen DR, Sharma V, Pulawa LK, Hays WR, Krezel W, Chambon P, Eckel RH. Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology. 2004 Aug; 145(8):3679-85.
    View in: PubMed
    Score: 0.012
  13. McDermott NB, Gordon DF, Kramer CA, Liu Q, Linney E, Wood WM, Haugen BR. Isolation and functional analysis of the mouse RXRgamma1 gene promoter in anterior pituitary cells. J Biol Chem. 2002 Sep 27; 277(39):36839-44.
    View in: PubMed
    Score: 0.011
  14. Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 02; 32(2):153-163.
    View in: PubMed
    Score: 0.010
  15. Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 01 15; 27(2):585-597.
    View in: PubMed
    Score: 0.009
  16. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J Clin Invest. 2000 Jul; 106(1):73-9.
    View in: PubMed
    Score: 0.009
  17. Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 05 15; 25(10):3141-3151.
    View in: PubMed
    Score: 0.008
  18. Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 06; 28(6):739-747.
    View in: PubMed
    Score: 0.008
  19. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC. The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. Mol Endocrinol. 1997 Apr; 11(4):481-9.
    View in: PubMed
    Score: 0.007
  20. Haugen BR, McDermott MT, Gordon DF, Rupp CL, Wood WM, Ridgway EC. Determinants of thyrotrope-specific thyrotropin beta promoter activation. Cooperation of Pit-1 with another factor. J Biol Chem. 1996 Jan 05; 271(1):385-9.
    View in: PubMed
    Score: 0.007
  21. Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun; 6(2-3):87-99.
    View in: PubMed
    Score: 0.006
  22. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb; 100(2):E243-52.
    View in: PubMed
    Score: 0.006
  23. Haugen BR, Gordon DF, Nelson AR, Wood WM, Ridgway EC. The combination of Pit-1 and Pit-1T have a synergistic stimulatory effect on the thyrotropin beta-subunit promoter but not the growth hormone or prolactin promoters. Mol Endocrinol. 1994 Nov; 8(11):1574-82.
    View in: PubMed
    Score: 0.006
  24. Haugen BR, Wood WM, Gordon DF, Ridgway EC. A thyrotrope-specific variant of Pit-1 transactivates the thyrotropin beta promoter. J Biol Chem. 1993 Oct 05; 268(28):20818-24.
    View in: PubMed
    Score: 0.006
  25. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 01; 18(13):3580-91.
    View in: PubMed
    Score: 0.005
  26. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13; 25(16):2304-17.
    View in: PubMed
    Score: 0.003
  27. Gordon DF, Lewis SR, Haugen BR, James RA, McDermott MT, Wood WM, Ridgway EC. Pit-1 and GATA-2 interact and functionally cooperate to activate the thyrotropin beta-subunit promoter. J Biol Chem. 1997 Sep 26; 272(39):24339-47.
    View in: PubMed
    Score: 0.002
  28. Wood WM, Dowding JM, Bright TM, McDermott MT, Haugen BR, Gordon DF, Ridgway EC. Thyroid hormone receptor beta2 promoter activity in pituitary cells is regulated by Pit-1. J Biol Chem. 1996 Sep 27; 271(39):24213-20.
    View in: PubMed
    Score: 0.002
  29. Ng L, Forrest D, Haugen BR, Wood WM, Curran T. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone. Mol Endocrinol. 1995 Sep; 9(9):1202-13.
    View in: PubMed
    Score: 0.002
  30. Lossie AC, Haugen BR, Wood WM, Camper SA, Gordon DF. Chromosomal localization of the large subunit of mouse replication factor C in the mouse and human. Mamm Genome. 1995 Jan; 6(1):58-9.
    View in: PubMed
    Score: 0.002
  31. Wood WM, Dowding JM, Haugen BR, Bright TM, Gordon DF, Ridgway EC. Structural and functional characterization of the genomic locus encoding the murine beta 2 thyroid hormone receptor. Mol Endocrinol. 1994 Dec; 8(12):1605-17.
    View in: PubMed
    Score: 0.002
  32. Gordon DF, Haugen BR, Sarapura VD, Nelson AR, Wood WM, Ridgway EC. Analysis of Pit-1 in regulating mouse TSH beta promoter activity in thyrotropes. Mol Cell Endocrinol. 1993 Oct; 96(1-2):75-84.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)